Skip to main content
Defiance International

Published study records

Study records.

Identifier-confirmed and citation-only records have not passed evidence or citation verification. These checks do not establish evidence strength, efficacy, safety, or suitability.

Read each study in its experimental context. A shared molecule name or database link does not establish that our material matches a study's formulation, composition or preparation. Study findings are not measurements of our inventory, promises of a biological result or authorization to use our materials in humans or animals. Actual Product specifications and lot reports are separate records.

Study record counts

68,366 study records.

407 evidence-verified · 10,493 citation-verified · 57,416 identifier-confirmed · 50 citation-only

Listed by tier, then records with a public summary first, then publication year, newest first, undated last.

Verified records by research setting

  • Human research: 689
  • In vitro: 2,868
  • In vivo/preclinical: 3,719
  • Review/meta-analysis: 3,624
  • Other: 0
Filter study recordsReset filters

Filtered results

Study type: In vivo/preclinical · Verification: Citation verified

  • 2019

Effect of cerebrolysin on bladder function after spinal cord injury in female Wistar rats

International journal of urology : official journal of the Japanese Urological Association · 2019

Study scale: Not reported in the declared source.

Bibliographic details only: Open source record

No public summary

No plain-language summary is published in this record. Summary availability is separate from its verification. Consult the cited publication when a public link is available.

Limitations and uncertainty

Not reported in the declared source.

Citation verified. The PMID shown was confirmed at PubMed on 2026-08-16, and its study type matched the catalog’s source record. It is held as a citation, not evidence. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Study type: In vitro · Verification: Citation verified

  • 2019

Vasoactive Intestinal Peptide induces glucose and neutral amino acid uptake through mTOR signalling in human cytotrophoblast cells.

Scientific reports · 2019

Study scale: Not reported in the declared source.

Bibliographic details only: Open source record

No public summary

No plain-language summary is published in this record. Summary availability is separate from its verification. Consult the cited publication when a public link is available.

Limitations and uncertainty

Not reported in the declared source.

Citation verified. The PMID shown was confirmed at PubMed on 2026-08-16, and its study type matched the catalog’s source record. It is held as a citation, not evidence. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Study type: In vivo/preclinical · Verification: Citation verified

  • 2019

Developmental Exposure of Mice to T-2 Toxin Increases Astrocytes and Hippocampal Neural Stem Cells Expressing Metallothionein.

Neurotoxicity research · 2019

Study scale: Not reported in the declared source.

Bibliographic details only: Open source record

No public summary

No plain-language summary is published in this record. Summary availability is separate from its verification. Consult the cited publication when a public link is available.

Limitations and uncertainty

Not reported in the declared source.

Citation verified. The PMID shown was confirmed at PubMed on 2026-08-16, and its study type matched the catalog’s source record. It is held as a citation, not evidence. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Study type: Human research · Verification: Citation verified

  • 2019

Evaluation of plasma antimicrobial peptide LL-37 and nuclear factor-kappaB levels in stable chronic obstructive pulmonary disease.

International journal of chronic obstructive pulmonary disease · 2019

Study scale: Not reported in the declared source.

Bibliographic details only: Open source record

No public summary

No plain-language summary is published in this record. Summary availability is separate from its verification. Consult the cited publication when a public link is available.

Limitations and uncertainty

Not reported in the declared source.

Citation verified. The PMID shown was confirmed at PubMed on 2026-08-20, and its study type matched the catalog’s source record. It is held as a citation, not evidence. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Study type: Meta-analysis · Verification: Citation verified

  • Literature
  • 2019

Demographic, sampling- and assay-related confounders of endogenous oxytocin concentrations: A systematic review and meta-analysis.

Frontiers in neuroendocrinology · 2019

Study scale: Not reported in the declared source.

Bibliographic details only: Open source record

No public summary

No plain-language summary is published in this record. Summary availability is separate from its verification. Consult the cited publication when a public link is available.

Limitations and uncertainty

Not reported in the declared source.

Citation verified. The PMID shown was confirmed at PubMed on 2026-09-09, and its study type matched the catalog’s source record. It is held as a citation, not evidence. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Study type: Narrative review · Verification: Citation verified

  • 2019

The Critical Role of the Antimicrobial Peptide LL-37/ CRAMP in Protection of Colon Microbiota Balance, Mucosal Homeostasis, Anti-Inflammatory Responses, and Resistance to Carcinogenesis.

Critical reviews in immunology · 2019

Study scale: Not reported in the declared source.

Bibliographic details only: Open source record

No public summary

No plain-language summary is published in this record. Summary availability is separate from its verification. Consult the cited publication when a public link is available.

Limitations and uncertainty

Not reported in the declared source.

Citation verified. The PMID shown was confirmed at PubMed on 2026-08-16, and its study type matched the catalog’s source record. It is held as a citation, not evidence. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Study type: In vivo/preclinical · Verification: Citation verified

  • 2019

Su1539 – Pentadecapeptide Bpc 157 Counteracts Portal Hypertension, Caval Hypertension and Aortal Hypotension in Rats with Suprahepatic Occlusion of Inferior Caval Vein (Budd-Chiari Syndrome) in Rats

Gastroenterology · 2019

Study scale: Not reported in the declared source.

Bibliographic details only: Open source record

No public summary

No plain-language summary is published in this record. Summary availability is separate from its verification. Consult the cited publication when a public link is available.

Limitations and uncertainty

Not reported in the declared source.

Citation verified. The DOI shown was confirmed at Crossref on 2026-08-20, and its study type matched the catalog’s source record. It is held as a citation, not evidence. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Study type: In vitro · Verification: Citation verified

  • 2019

Inhibition of microRNA-34a mediates protection of thymosin beta 4 in endothelial progenitor cells against advanced glycation endproducts by targeting B-cell lymphoma 2.

Canadian journal of physiology and pharmacology · 2019

Study scale: Not reported in the declared source.

Bibliographic details only: Open source record

No public summary

No plain-language summary is published in this record. Summary availability is separate from its verification. Consult the cited publication when a public link is available.

Limitations and uncertainty

Not reported in the declared source.

Citation verified. The PMID shown was confirmed at PubMed on 2026-08-16, and its study type matched the catalog’s source record. It is held as a citation, not evidence. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Study type: In vivo/preclinical · Verification: Citation verified

  • 2019

Earlier changes in mice after D-galactose treatment were improved by mitochondria derived small peptide MOTS-c.

Biochemical and biophysical research communications · 2019

Study scale: Not reported in the declared source.

Bibliographic details only: Open source record

No public summary

No plain-language summary is published in this record. Summary availability is separate from its verification. Consult the cited publication when a public link is available.

Limitations and uncertainty

Not reported in the declared source.

Citation verified. The PMID shown was confirmed at PubMed on 2026-08-16, and its study type matched the catalog’s source record. It is held as a citation, not evidence. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Study type: Narrative review · Verification: Citation verified

  • Literature
  • 2019

Cellular Mechanisms for Antinociception Produced by Oxytocin and Orexins in the Rat Spinal Lamina II-Comparison with Those of Other Endogenous Pain Modulators.

Pharmaceuticals (Basel, Switzerland) · 2019

Study scale: Not reported in the declared source.

Bibliographic details only: Open source record

No public summary

No plain-language summary is published in this record. Summary availability is separate from its verification. Consult the cited publication when a public link is available.

Limitations and uncertainty

Not reported in the declared source.

Citation verified. The PMID shown was confirmed at PubMed on 2026-09-09, and its study type matched the catalog’s source record. It is held as a citation, not evidence. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Study type: In vivo/preclinical · Verification: Citation verified

  • 2019

Su1526 – Complications of Portal Triad Obstruction and Reperfusion in Rats. Pentadecapeptide Bpc 157 Counteracts Venous and Arterial Thrombosis and Arrhythmias

Gastroenterology · 2019

Study scale: Not reported in the declared source.

Bibliographic details only: Open source record

No public summary

No plain-language summary is published in this record. Summary availability is separate from its verification. Consult the cited publication when a public link is available.

Limitations and uncertainty

Not reported in the declared source.

Citation verified. The DOI shown was confirmed at Crossref on 2026-08-20, and its study type matched the catalog’s source record. It is held as a citation, not evidence. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Study type: Narrative review · Verification: Citation verified

  • 2019

Mitochondrial-derived peptide humanin as therapeutic target in cancer and degenerative diseases.

Expert opinion on therapeutic targets · 2019

Study scale: Not reported in the declared source.

Bibliographic details only: Open source record

No public summary

No plain-language summary is published in this record. Summary availability is separate from its verification. Consult the cited publication when a public link is available.

Limitations and uncertainty

Not reported in the declared source.

Citation verified. The PMID shown was confirmed at PubMed on 2026-08-16, and its study type matched the catalog’s source record. It is held as a citation, not evidence. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.